This year, PHARMAC is reviewing the way we seek and incorporate the consumer voice in our work, and is asking people about how we could improve input from, or engagement with, them.
PHARMAC is pleased that the Government has announced an uplift in PHARMAC’s funding.
Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions. The first decision is to fund a medication for treating a degenerative eye condition, and the second is to fund another oral anticoagulant option for the prevention of strokes and the prevention or treatment of blood clots.
PHARMAC and Ngā Kaitiaki o Te Puna Rongoā ō Āotearoa (Māori Pharmacists Association) recently celebrated the 10th year of the Hiwinui Heke, Māori Pharmacy Student Scholarships in Rotorua.
The influenza vaccine used in New Zealand this year will include protection against infection with four strains of the virus.
A decision to widen access to Truvada to prevent infection with HIV is a great opportunity to reduce transmission rates of HIV infections in New Zealand, says PHARMAC Chief Executive Sarah Fitt.
PHARMAC is supporting New Zealand’s first Pacific pharmacists' group to establish itself as a formal entity.
Funding cetuximab for patients with head and neck cancer will be a significant advance for treating this type of cancer in New Zealand, says PHARMAC Director of Operations Sarah Fitt.
Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones.
Achieving equity in medicines access is one of the bold goals PHARMAC has set itself to achieve by 2025.
PHARMAC is welcoming the presentation of results from the international SOLD trial, comparing short and long duration treatment with trastuzumab (Herceptin) for early HER 2-positive breast cancer.
PHARMAC is giving people a choice of four funded CareSens meters, including a dual meter that measures both blood glucose and ketones.
Stuart McLauchlan Chair PHARMAC today announced that Sarah Fitt, Director of Operations will be appointed as PHARMAC's new Chief Executive effective from Saturday 6 January 2018
PHARMAC has announced today that its Chief Executive, Steffan Crausaz, will be stepping down to take up a new role in the private-sector in New Zealand.
Over 600,000 New Zealanders will be able to avoid the often painful and debilitating shingles infection following PHARMAC’s decision to fully fund the shingles vaccine.
Hundreds of people with diabetes are set to benefit from the funding of a new treatment that will help prevent blindness.
From 1 November 2017 dexamethasone implants (brand name Ozurdex) will be funded for eligible people with diabetic macular oedema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.
Article based on an interview with Prof. Keith Petrie about generic medicines and how prescribers’ own views about generic medicines can affect patient outcomes.
Thousands of children a year are set to avoid chickenpox infection, with flow-on benefits to families and the wider health system, after the varicella vaccine which prevents chickenpox is funded from 1 July 2017.
PHARMAC has announced the funding of five new treatments and wider use of over 30 existing treatments, which are set to benefit many New Zealanders from 1 July 2017.
PHARMAC is pleased to confirm a long-term supply for metoprolol succinate. From 1 March 2018, AstraZeneca will be the sole-supplier of metoprolol succinate in New Zealand, with its brand Betaloc-CR.